• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by DermTech Inc.

    4/26/24 6:19:55 PM ET
    $DMTK
    Medical Specialities
    Health Care
    Get the next $DMTK alert in real time by email
    SC 13G 1 tm2412585d1_sc13g.htm SC 13G

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No.   )*

     

    DermTech, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    24984K105

    (CUSIP Number)

     

    April 19, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosure provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.)

     

     

     

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    Van Herk Investments B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power

    1,778,057

     
    6 Shared Voting Power
    0
     
    7 Sole Dispositive Power

    1,778,057

     
    8 Shared Dispositive Power
    0
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:

    1,778,057

     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    2

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    Van Herk Investments THI B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,778,057
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,778,057
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,778,057
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    3

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    Van Herk Private Equity Investments B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,778,057
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,778,057
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,778,057
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    4

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    Stichting Administratiekantoor Penulata
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,778,057
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,778,057
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,778,057
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    OO
                   

     

    5

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    Van Herk Management Services B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,778,057
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,778,057
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,778,057
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    6

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,778,057
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,778,057
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,778,057
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    7

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    A. van Herk Holding B.V.
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,778,057
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,778,057
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,778,057
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    CO
                   

     

    8

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    Stichting Administratiekantoor Abchrys
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,778,057
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,778,057
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,778,057
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    OO
                   

     

    9

     

     

    CUSIP No. 24984K105 13G  
     
      1 Name of Reporting Person
    Adrianus van Herk
     
      2 Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o
        (b) o
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization:
    The Netherlands
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    0
     
    6 Shared Voting Power
    1,778,057
     
    7 Sole Dispositive Power
    0
     
    8 Shared Dispositive Power
    1,778,057
     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person:
    1,778,057
     
      10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9):
    5.1%
     
      12 Type of Reporting Person (See Instructions)
    IN
                   

     

    10

     

     

    CUSIP No. 24984K105 13G  

     

    Item 1.
      (a) Name of Issuer:
    DermTech, Inc., a Delaware corporation
      (b)

    Address of Issuer’s Principal Executive Offices:

    12340 El Camino Real

    San Diego, CA 92130

     
    Item 2.
      (a)

    Names of Persons Filing:

    This statement is being filed by (i) Van Herk Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHI”), with respect to Common Stock (as defined below) beneficially owned by it, (ii) Van Herk Investments THI B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHIT”), with respect to Common Stock beneficially owned by VHI, (iii) Van Herk Private Equity Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHPI”), with respect to Common Stock beneficially owned by VHI and VHIT, (iv) Stichting Administratiekantoor Penulata, a foundation organized under the laws of the Netherlands (“Penulata”), with respect to Common Stock beneficially owned by VHI, VHIT and VHPI, (v) Van Herk Management Services B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHMS”), with respect to Common Stock beneficially owned by VHI, VHIT and VHPI, (vi) Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V., a private company with limited liability incorporated under the laws of the Netherlands (“OGBBA”), with respect to Common Stock beneficially owned by VHI, VHIT, VHPI and VHMS, (vii) A. van Herk Holding B.V., a private company with limited liability incorporated under the laws of the Netherlands (“Holdings”), with respect to Common Stock beneficially owned by VHI, VHIT, VHPI, VHMS and OGBBA, (viii) Stichting Administratiekantoor Abchrys, a foundation organized under the laws of the Netherlands (“Abchrys”), with respect to Common Stock beneficially owned by VHI, VHIT, VHPI, VHMS, OGBBA and Holdings, and (ix) Adrianus van Herk (“Mr. van Herk”) with respect to Common Stock beneficially owned by VHI, VHIT, VHPI, VHMS, OGBBA, Holdings, Penulata and Abchrys.

     

    Mr. van Herk is (i) an investor, (ii) the holder of all of the depositary receipts issued by Penulata and Abchrys, (iii) the sole board member of Penulata and Abchrys, and (iv) the sole managing director of VHMS, OGBBA and Holdings. Penulata holds substantially all of the issued and outstanding shares of VHPI. VHPI is the sole shareholder of VHIT. VHIT is the sole shareholder of VHI. VHI is principally engaged in making investments. Abchrys holds substantially all of the issued and outstanding shares of Holdings. Holdings is the sole shareholder of OGBBA. OGBBA is the sole shareholder of VHMS and is principally engaged in making investments. VHMS is the sole managing director of VHI, VHIT and VHPI.

     

    Each of Mr. van Herk, VHIT, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys disclaims beneficial ownership of the securities covered by this statement.

      (b)

    Address of Principal Business Office or, if none, Residence:

    The principal business address of each of Mr. van Herk, VHI, VHIT, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys is:

     

    Lichtenauerlaan 30

    3062 ME Rotterdam

    The Netherlands

      (c) Citizenship:
    Each of VHI, VHIT, VHPI, VHMS, OGBBA and Holdings is a private company with limited liability incorporated under the laws of the Netherlands.  Penulata and Abchrys are Netherlands foundations.  Mr. van Herk is a citizen of the Netherlands.
      (d) Title of Class of Securities:
    Common Stock, par value $0.0001 per share (the “Common Stock”).
      (e) CUSIP Number:
    24984K105

     

    11

     

     

    CUSIP No. 24984K105 13G  

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       
        o Broker or dealer registered under section 15 of the Act;
           
        o Bank as defined in section 3(a)(6) of the Act;
           
        o Insurance company as defined in section 3(a)(19) of the Act;
           
        o Investment company registered under section 8 of the Investment Company Act of 1940;
           
        o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
        o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
        o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
        o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
        o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
           
        o A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
        o Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:____________________________
           
    Item 4. Ownership
     
      (a) Amount beneficially owned:
    1,778,057 shares of Common Stock
      (b) Percent of class:
    5.1% (The percentages used in this statement are calculated based upon the 34,623,443 shares of Common Stock issued and outstanding as of February 23, 2024, as reported by DermTech, Inc. in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2024.)
      (c) Number of shares as to which such person has:
     
      VHI
        i. Sole power to vote or direct the vote:
    1,778,057
        ii. Shared power to vote or direct the vote:
    0
        iii. Sole power to dispose or direct the disposition of:
    1,778,057
        iv. Shared power to dispose or direct the disposition of:
    0
           

     

    12

     

     

    CUSIP No. 24984K105 13G  

     

      VHI has the sole power to vote or direct the vote, and to dispose or to direct the disposition of, the Common Stock beneficially owned by it.

     

      VHIT
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    1,778,057
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    1,778,057
      VHIT shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in VHI.

     

      VHPI
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    1,778,057
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    1,778,057
      VHPI shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in VHIT.
       
      Penulata
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    1,778,057
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    1,778,057
      Penulata shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in VHPI.
       
      VHMS
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    1,778,057
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    1,778,057
      VHMS shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of it being the sole managing director of VHI, VHIT and VHPI.
       
      OGBBA
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    1,778,057
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    1,778,057
      OGBBA shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in VHMS.
       
      Holdings
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    1,778,057

     

    13

     

     

    CUSIP No. 24984K105 13G  

     

        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    1,778,057
      Holdings shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in OGBBA.
       
      Abchrys
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    1,778,057
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    1,778,057
      Abchrys shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in Holdings.
       
      Mr. van Herk
       
        i. Sole power to vote or direct the vote:
    0
        ii. Shared power to vote or direct the vote:
    1,778,057
        iii. Sole power to dispose or direct the disposition of:
    0
        iv. Shared power to dispose or direct the disposition of:
    1,778,057
      Mr. van Herk shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of his holding of all of the depositary receipts issued by Penulata and Abchrys, his being the sole board member of Penulata and Abchrys, and his being the sole managing director of VHMS, OGBBA and Holdings.
       
    Item 5. Ownership Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ¨.
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not Applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not Applicable.
     
    Item 8. Identification and Classification of Members of the Group
       
      Not Applicable.
     
    Item 9. Notice of Dissolution of Group
       
      Not Applicable.

     

    14

     

     

    CUSIP No. 24984K105 13G  

     

    Item 10. Certification
       
    By signing below we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    15

     

     

    CUSIP No. 24984K105 13G  

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 26, 2024

     

      VAN HERK INVESTMENTS B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      VAN HERK INVESTMENTS THI B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      VAN HERK PRIVATE EQUITY INVESTMENTS B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      STICHTING ADMINISTRATIEKANTOOR PENULATA
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      VAN HERK MANAGEMENT SERVICES B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      ONROEREND GOED BEHEER- EN
      BELEGGINGSMAATSCHAPPIJ A. VAN HERK B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      A. VAN HERK HOLDING B.V.
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*

     

     

    * Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.

     

    16

     

     

    CUSIP No. 24984K105 13G  

     

      STICHTING ADMINISTRATIEKANTOOR ABCHRYS
       
       
      By: /s/ Erik G.A. Esveld
        Name: Erik G.A. Esveld
        Title: Attorney-In-Fact*
         
         
      ADRIANUS VAN HERK
       
       
      By: /s/ Erik G.A. Esveld
      Name: Erik G.A. Esveld
      Title: Attorney-In-Fact*

     

     

    * Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.

     

    [Signature Page to Schedule 13G]

     

    17

     

     

    CUSIP No. 24984K105 13G  

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Title
         
    99.1   Joint Filing Agreement, dated April 26, 2024, by and among the Reporting Persons, as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
         
    99.2   Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons, incorporated by reference herein by reference to Exhibit 99.2 to Amendment No. 3 to Schedule 13G filed by the Reporting Persons on September 17, 2019 with respect to Zealand Pharma A/S (File No. 001-38178).

     

    18

     

    Get the next $DMTK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DMTK

    DatePrice TargetRatingAnalyst
    7/18/2022$48.00Outperform
    Oppenheimer
    6/14/2022$38.00 → $19.00Buy
    BTIG Research
    1/7/2022$26.00Overweight
    Stephens
    1/7/2022Overweight
    Stephens & Co.
    10/15/2021$50.00Outperform
    Cowen
    More analyst ratings

    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on DermTech with a new price target

      Oppenheimer resumed coverage of DermTech with a rating of Outperform and set a new price target of $48.00

      7/18/22 9:13:48 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • BTIG Research reiterated coverage on DermTech with a new price target

      BTIG Research reiterated coverage of DermTech with a rating of Buy and set a new price target of $19.00 from $38.00 previously

      6/14/22 8:37:49 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • Stephens initiated coverage on DermTech with a new price target

      Stephens initiated coverage of DermTech with a rating of Overweight and set a new price target of $26.00

      1/7/22 7:32:05 AM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DermTech Files for Voluntary Chapter 11 Protection

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets. Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets. DermTech

      6/18/24 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Reports First-Quarter 2024 Financial Results

      - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year - Test revenue increased 7 percent versus the first quarter of 2023 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. Total revenue was $3.8 million, an 11 percent increase from

      5/14/24 4:05:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in

      4/18/24 4:15:00 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    SEC Filings

    See more
    • DermTech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/20/24 4:03:19 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - DermTech, Inc. (0001651944) (Filer)

      6/18/24 8:10:13 AM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Other Events

      8-K - DermTech, Inc. (0001651944) (Filer)

      5/17/24 4:05:27 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Sun Kevin M covered exercise/tax liability with 445 shares, decreasing direct ownership by 0.17% to 269,216 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/12/24 8:07:07 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Akhavan Ramin covered exercise/tax liability with 3,745 shares, decreasing direct ownership by 3% to 128,425 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:06:44 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • Sun Kevin M covered exercise/tax liability with 4,945 shares, decreasing direct ownership by 2% to 269,661 units (SEC Form 4)

      4 - DermTech, Inc. (0001651944) (Issuer)

      6/7/24 8:04:16 PM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Financials

    Live finance-specific insights

    See more
    • DermTech to Explore Strategic Alternatives and Implement Restructuring Plan

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring strategic alternatives to maximize stockholder value. Potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, licensing or other transaction involving the Company. There can be no assurance, however, that the strategic review process will result in any such transaction or if a transaction is undertaken, that such transaction would close in

      4/18/24 4:15:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Reports Fourth-Quarter 2023 Financial Results

      - Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year - Test revenue increased 38 percent versus the fourth quarter of 2022 - Estimated cash runway into the first quarter of 2025 DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. "We reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (ASP) and revenue growth in 2024," said Bret Christensen, CEO, DermTech. "We've aligned our commer

      2/29/24 4:01:00 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Announces Release Date for Fourth-quarter 2023 Financial Results

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release. For participants interested in asking questions during the teleconference, please register using the following link. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during

      2/13/24 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Leadership Updates

    Live Leadership Updates

    See more
    • DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for

      11/7/23 4:13:58 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises DermTech, Inc. ("DermTech" or the "Company") (NASDAQ:DMTK) investors that a lawsuit filed on behalf of investors that purchased DermTech securities between May 3, 2022 through November 3, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options

      10/18/23 3:55:34 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • DermTech Appoints Mark Aguillard as Chief Commercial Officer

      DermTech, Inc. (NASDAQ:DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech's overall commercial strategy and execution. Commenting on Mr. Aguillard's appointment, Bret Christensen, DermTech's CEO said, "I'd like to welcome Mark to the team. We are confident that his demonstrated success and wide breadth of commercial and payer access experience will serve us well during this transformational period as we focus on generating reimbursed tests to grow revenue. Mark's leadership will be i

      9/11/23 8:05:00 AM ET
      $DMTK
      Medical Specialities
      Health Care

    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by DermTech Inc.

      SC 13G - DermTech, Inc. (0001651944) (Subject)

      4/26/24 6:19:55 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by DermTech Inc. (Amendment)

      SC 13G/A - DermTech, Inc. (0001651944) (Subject)

      2/8/24 5:18:40 PM ET
      $DMTK
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by DermTech Inc. (Amendment)

      SC 13D/A - DermTech, Inc. (0001651944) (Subject)

      12/12/23 4:19:36 PM ET
      $DMTK
      Medical Specialities
      Health Care